Перитонеальний діаліз та перитонеальний фіброз: молекулярні механізми, фактори ризику та перспектива профілактики

DOI: https://doi.org/10.31450/ukrjnd.4(76).2022.10
Ключові слова: перитонеальний діаліз, перитонеальна мембрана, фіброз, цитокіни, фактори росту, фактори ризику, глюкоза, недостатність ультрафільтрації, профілактика.

Анотація

Лікування методом перитонеального діалізу (ПД) викликає структурні та функціональні зміни перитонеальної мембрани, кінцевою точкою яких є перитонеальний фіброз. Перитонеальний фіброз діагностується у 50% і 80% ПД пацієнтів протягом одного та двох років лікування, відповідно. Ключову роль в індукції перитонеального фіброзу відіграє мезотеліально-мезенхімальна трансформація, яка являє собою складний біологічний процес переходу мезотелію в мезенхім. У цьому огляді підсумовано сучасні знання щодо змін функції та морфології перитонеуму, молекулярні механізми розвитку перитонеального фіброзу та його клінічні наслідки з часом лікування ПД. Особлива увага приділяється доведеним та можливим факторам ризику перитонеального фіброзу, розглядаються наявні та перспективні стратегії профілактики.

Завантаження

Дані завантаження ще не доступні.

Посилання

Balzer MS. Molecular pathways in peritoneal fibrosis. Cell Signal. 2020;75:109778. doi: 10.1016/j.cellsig.2020.109778.

Bello AK, Okpechi IG, Osman MA, Cho Y, Cullis B, Htay H, et al. Epidemiology of peritoneal dialysis outcomes. Nat Rev Nephrol. 2022;18(12):779-793. doi: 10.1038/s41581-022-00623-7.

Bajo MA, Del Peso G, Teitelbaum I. Peritoneal Membrane Preservation. Semin Nephrol. 2017;37(1):77-92. doi: 10.1016/j.semnephrol.2016.10.009.

Perl J, Bargman JM. Peritoneal dialysis: from bench to bedside and bedside to bench. Am J Physiol Renal Physiol. 2016;311(5):F999-F1004. doi: 10.1152/ajprenal.00012.2016.

Chugh S, Chaudhry S, Ryan T, et al. Peritoneal Membrane Injury and Peritoneal Dialysis. Advances in Nephrology 2014;2014:573685. doi: 10.1155/2014/573685.

Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol. 2002;13(2):470-479. doi: 10.1681/ASN.V132470.

Farhat K, Stavenuiter AW, Beelen RH, Ter Wee PM. Pharmacologic targets and peritoneal membrane remodeling. Perit Dial Int. 2014;34(1):114-23. doi: 10.3747/pdi.2011.00332.

Tomino Y. Mechanisms and interventions in peritoneal fibrosis. Clin Exp Nephrol. 2012;16(1):109-14. doi: 10.1007/s10157-011-0533-y.

Masola V, Bonomini M, Borrelli S, Di Liberato L, Vecchi L, Onisto M, et al. Fibrosis of Peritoneal Membrane as Target of New Therapies in Peritoneal Dialysis. Int J Mol Sci. 2022;23(9):4831. doi: 10.3390/ijms23094831.

Costa CFFA, Sampaio-Maia B, Araujo R, Nascimento DS, Ferreira-Gomes J, Pestana M, et al. Gut Microbiome and Organ Fibrosis. Nutrients. 2022;14(2):352. doi: 10.3390/nu14020352.

Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214(2):199-210. doi: 10.1002/path.2277.

Terri M, Trionfetti F, Montaldo C, Cordani M, Tripodi M, Lopez-Cabrera M, et al. Mechanisms of Peritoneal Fibrosis: Focus on Immune Cells-Peritoneal Stroma Interactions. Front Immunol. 2021;12:607204. doi: 10.3389/fimmu.2021.607204.

Strippoli R, Moreno-Vicente R, Battistelli C, Cicchini C, Noce V, Amicone L, et al. Molecular Mechanisms Underlying Peritoneal EMT and Fibrosis. Stem Cells Int. 2016;2016:3543678. doi: 10.1155/2016/3543678.

Yung S, Chan TM. Pathophysiological changes to the peritoneal membrane during PD-related peritonitis: the role of mesothelial cells. Mediators Inflamm. 2012;2012:484167. doi: 10.1155/2012/484167.

López-Cabrera M. Mesenchymal Conversion of Mesothelial Cells Is a Key Event in the Pathophysiology of the Peritoneum during Peritoneal Dialysis. Adv Med. 2014;2014:473134. doi: 10.1155/2014/473134.

Del Peso G, Jiménez-Heffernan JA, Bajo MA, Aroeira LS, Aguilera A, Fernández-Perpén A, et al. Epithelial-to-mesenchymal transition of mesothelial cells is an early event during peritoneal dialysis and is associated with high peritoneal transport. Kidney Int Suppl. 2008;(108):S26-33. doi: 10.1038/sj.ki.5002598.

Mutsaers SE, Prêle CM, Pengelly S, Herrick SE. Mesothelial cells and peritoneal homeostasis. Fertil Steril. 2016;106(5):1018-1024. doi: 10.1016/j.fertnstert.2016.09.005.

Hong FY, Bao JF, Hao J, Yu Q, Liu J. Methylglyoxal and advanced glycation end-products promote cytokines expression in peritoneal mesothelial cells via MAPK signaling. Am J Med Sci. 2015;349(2):105-9. doi: 10.1097/MAJ.0000000000000394.

Ranzinger J, Rustom A, Schwenger V. Membrane nanotubes between peritoneal mesothelial cells: functional connectivity and crucial participation during inflammatory reactions. Front Physiol. 2014;5:412. doi: 10.3389/fphys.2014.00412.

Krediet RT. Aging of the Peritoneal Dialysis Membrane. Front Physiol. 2022;13:885802. doi: 10.3389/fphys.2022.885802.

Ogata R, Hiramatsu N, Hayakawa K, Nakajima S, Yao J, Kobayashi T, etal. Impairment of MCP-1 expression in mesothelial cells exposed to peritoneal dialysis fluid by osmotic stress and acidic stress. Perit Dial Int. 2011;31(1):80-9. doi: 10.3747/pdi.2009.00159.

Angsana J, Chen J, Liu L, Haller CA, Chaikof EL. Efferocytosis as a regulator of macrophage chemokine receptor expression and polarization. Eur J Immunol. 2016;46(7):1592-9. doi: 10.1002/eji.201546262.

Ditsawanon P, Aramwit P. Preserving the peritoneal membrane in long-term peritoneal dialysis patients. J Clin Pharm Ther. 2015;40(5):508-516. doi: 10.1111/jcpt.12318.

Wen Y, Guo Q, Yang X, Wu X, Feng S, Tan J, et al.High glucose concentrations in peritoneal dialysate are associated with all-cause and cardiovascular disease mortality in continuous ambulatory peritoneal dialysis patients. Perit Dial Int. 2015;35(1):70-7. doi: 10.3747/pdi.2013.00083.

Krediet RT. Acquired Decline in Ultrafiltration in Peritoneal Dialysis: The Role of Glucose. J Am Soc Nephrol. 2021;32(10):2408-2415. doi: 10.1681/ASN.2021010080.

Roumeliotis S, Dounousi E, Salmas M, Eleftheriadis T, Liakopoulos V. Unfavorable Effects of Peritoneal Dialysis Solutions on the Peritoneal Membrane: The Role of Oxidative Stress. Biomolecules. 2020;10(5):768. doi: 10.3390/biom10050768.

Adams JN, Martelle SE, Raffield LM, Freedman BI, Langefeld CD, Hsu FC, et al. Analysis of advanced glycation end products in the DHS Mind Study. J Diabetes Complications. 2016;30(2):262-8. doi: 10.1016/j.jdiacomp.2015.11.025.

He Z, Potter R, Li X, Flessner M. Stretch of human mesothelial cells increases cytokine expression. Adv Perit Dial. 2012;28:2-9.

Jufri NF, Mohamedali A, Avolio A, Baker MS. Mechanical stretch: physiological and pathological implications for human vascular endothelial cells. Vasc Cell. 2015;7:8. doi: 10.1186/s13221-015-0033-z.

Santos A, Lagares D. Matrix Stiffness: the Conductor of Organ Fibrosis. Curr Rheumatol Rep. 2018;20(1):2. doi: 10.1007/s11926-018-0710-z.

Szeto CC, Li PK. Peritoneal Dialysis-Associated Peritonitis. Clin J Am Soc Nephrol. 2019;14(7):1100-1105. doi: 10.2215/CJN.14631218.

Mutsaers HA, Stribos EG, Glorieux G, Vanholder R, Olinga P. Chronic Kidney Disease and Fibrosis: The Role of Uremic Retention Solutes. Front Med (Lausanne). 2015;2:60. doi: 10.3389/fmed.2015.00060.

Mazur  T,  Demikhova  N,  Rudenko  T,  Yurchenko  A,  Yezhova  O,  Bokova  S,  et al. Chronic inflammation and progression of chronic kidney disease in patients with type 2 diabetes. Ukr J Nephr Dial. 2021;4(72):36-43. doi: 10.31450/ukrjnd.4(72).2021.05.

Stepanova N. Role of Impaired Oxalate Homeostasis in Cardiovascular Disease in Patients With End-Stage Renal Disease: An Opinion Article. Front Pharmacol. 2021;12:692429. doi: 10.3389/fphar.2021.692429.

Demikhova N, Sukhonos V, Vynnychenko L, Psareva V, Prikhodko O. Activation of lipid peroxidation in patients with renal hypertension. Georgian Med News. 2013;(215):51-55. [In Russian].

Asgharzadeh F, Bargi R, Hosseini M, Farzadnia M, Khazaei M. Cardiac and renal fibrosis and oxidative stress balance in lipopolysaccharide-induced inflammation in male rats. ARYA Atheroscler. 2018;14(2):71-77. doi: 10.22122/arya.v14i2.1550.

Nakano T, Watanabe H, Imafuku T, Tokumaru K, Fujita I, Arimura N, etal. Indoxyl Sulfate Contributes to mTORC1-Induced Renal Fibrosis via The OAT/NADPH Oxidase/ROS Pathway. Toxins (Basel). 2021;13(12):909. doi: 10.3390/toxins13120909.

Kim SH, Yu MA, Ryu ES, Jang YH, Kang DH. Indoxyl sulfate-induced epithelial-to-mesenchymal transition and apoptosis of renal tubular cells as novel mechanisms of progression of renal disease. Lab Invest. 2012;92(4):488-98. doi: 10.1038/labinvest.2011.194.

Huang G, Wang Y, Shi Y, Ma X, Tao M, Zang X, et al. The prognosis and risk factors of baseline high peritoneal transporters on patients with peritoneal dialysis. J Cell Mol Med. 2021;25(18):8628-8644. doi: 10.1111/jcmm.16819.

He S, Xiong Q, Li L, Lin X, Zhao J, Guo X, et al. Increased risk of modality failure with higher serum uric acid level in continuous ambulatory peritoneal dialysis patients: a prospective cohort study. Ren Fail. 2022;44(1):272-281. doi: 10.1080/0886022X.2022.2035762.

Stepanova N, Snisar L, Lebid L. Hyperuricemia Predicts Residual Diuresis Decline in Peritoneal Dialysis Patients. Electron J Gen Med. 2021;18(1):em270. doi: 10.29333/ejgm/9297.

Convento MB, Pessoa EA, Cruz E, da Glória MA, Schor N, Borges FT. Calcium oxalate crystals and oxalate induce an epithelial-to-mesenchymal transition in the proximal tubular epithelial cells: Contribution to oxalate kidney injury. Sci Rep. 2017;7:45740. doi: 10.1038/srep45740.

Xie J, Ye Z, Li L, Xia Y, Yuan R, Ruan Y, et al. Ferrostatin‑1 alleviates oxalate‑induced renal tubular epithelial cell injury, fibrosis and calcium oxalate stone formation by inhibiting ferroptosis. Mol Med Rep. 2022;26(2):256. doi: 10.3892/mmr.2022.12772.

Stepanova N, Korol L, Lebid L, Snisar L, Savchenko S. Oxalate Balance in Peritoneal Dialysis Patients: A Potential Role of Dialysis-related Peritonitis. In Vivo. 2022;36(2):925-933. doi: 10.21873/invivo.12782.

Stepanova N, Korol L,Tolstanova G, Akulenko I.Oxalate-Degrading Activity in Fecal Microbiota is Associated With High Serum Indoxyl Sulfate and Plasma Oxalic Acid Concentrations in Dialysis Patients. AJKD. 2022;79(4, Suppl 2):S13. doi: 10.1053/j.ajkd.2022.01.046.

Piccapane F, Bonomini M, Castellano G, Gerbino A, Carmosino M, Svelto M, et al. A Novel Formulation of Glucose-Sparing Peritoneal Dialysis Solutions with l-Carnitine Improves Biocompatibility on Human Mesothelial Cells. Int J Mol Sci. 2020;22(1):123. doi: 10.3390/ijms22010123.

Rago C, Lombardi T, Di Fulvio G, Di Liberato L, Arduini A, Divino-Filho JC, et al. A New Peritoneal Dialysis Solution Containing L-Carnitine and Xylitol for Patients on Continuous Ambulatory Peritoneal Dialysis: First Clinical Experience. Toxins (Basel). 2021;13(3):174. doi: 10.3390/toxins13030174.

van Westrhenen R, Zweers MM, Kunne C, de Waart DR, van der Wal AC, Krediet RT. A pyruvate-buffered dialysis fluid induces less peritoneal angiogenesis and fibrosis than a conventional solution. Perit Dial Int. 2008;28(5):487-96.

Bazzato G, Fracasso A, Gambaro G, Baggio B. Use of glycosaminoglycans to increase efficiency of long-term continuous peritoneal dialysis. Lancet. 1995;346(8977):740-1. doi: 10.1016/s0140-6736(95)91506-0.

Gozdzikiewicz J, Borawski J, Mysliwiec M. Pleiotropic effects of heparin and heparinoids in peritoneal dialysis. Clin Appl Thromb Hemost. 2009;15(1):92-7. doi: 10.1177/1076029607304722.

Herzog R, Bartosova M, Tarantino S, Wagner A, Unterwurzacher M, Sacnun JM, et al. Peritoneal Dialysis Fluid Supplementation with Alanyl-Glutamine Attenuates Conventional Dialysis Fluid-Mediated Endothelial Cell Injury by Restoring Perturbed Cytoprotective Responses. Biomolecules. 2020;10(12):1678. doi: 10.3390/biom10121678.

Wiesenhofer FM, Herzog R, Boehm M, Wagner A, Unterwurzacher M, Kasper DC, et al. Targeted Metabolomic Profiling of Peritoneal Dialysis Effluents Shows Anti-oxidative Capacity of Alanyl-Glutamine. Front Physiol. 2019;9:1961. doi: 10.3389/fphys.2018.01961.

Terawaki H, Hayashi Y, Zhu WJ, Matsuyama Y, Terada T, Kabayama S, et al. Transperitoneal administration of dissolved hydrogen for peritoneal dialysis patients: a novel approach to suppress oxidative stress in the peritoneal cavity. Med Gas Res. 2013;3(1):14. doi: 10.1186/2045-9912-3-14.

Nakayama M, Zhu WJ, Watanabe K, Gibo A, Sherif AM, Kabayama S, et al. Dissolved molecular hydrogen (H2) in Peritoneal Dialysis (PD) solutions preserves mesothelial cells and peritoneal membrane integrity. BMC Nephrol. 2017;18(1):327. doi: 10.1186/s12882-017-0741-0.

Herzog R, Sacnun JM, González-Mateo G, Bartosova M, Bialas K, Wagner A, et al. Lithium preserves peritoneal membrane integrity by suppressing mesothelial cell αB-crystallin. Sci Transl Med. 2021;13(608):eaaz9705. doi: 10.1126/scitranslmed.aaz9705.

Balzer MS, Rong S, Nordlohne J, Zemtsovski JD, Schmidt S, Stapel B, et al. SGLT2 Inhibition by Intraperitoneal Dapagliflozin Mitigates Peritoneal Fibrosis and Ultrafiltration Failure in a Mouse Model of Chronic Peritoneal Exposure to High-Glucose Dialysate. Biomolecules. 2020;10(11):1573. doi: 10.3390/biom10111573.

Martus G, Bergling K, de Arteaga J, Öberg CM. SGLT2 inhibition does not reduce glucose absorption during experimental peritoneal dialysis. Perit Dial Int. 2021;41(4):373-380. doi: 10.1177/08968608211008095.

Jing S, Kezhou Y, Hong Z, Qun W, Rong W. Effect of renin-angiotensin system inhibitors on prevention of peritoneal fibrosis in peritoneal dialysis patients. Nephrology (Carlton). 2010;15(1):27-32. doi: 10.1111/j.1440-1797.2009.01162.x.

Kolesnyk I, Noordzij M, Dekker FW, Boeschoten EW, Krediet RT. A positive effect of AII inhibitors on peritoneal membrane function in long-term PD patients. Nephrol Dial Transplant. 2009;24(1):272-7. doi: 10.1093/ndt/gfn421.

Aponte M, Murru N, Shoukat M. Therapeutic, Prophylactic, and Functional Use of Probiotics: A Current Perspective. Front Microbiol. 2020;11:562048. doi: 10.3389/fmicb.2020.562048.


Переглядів анотації: 555
Завантажень PDF: 5697
Опубліковано
2022-06-05
Як цитувати
Stepanova, N., Snisar, L., & Burdeyna, O. (2022). Перитонеальний діаліз та перитонеальний фіброз: молекулярні механізми, фактори ризику та перспектива профілактики. Український Журнал Нефрології та Діалізу, (4(76), 81-90. https://doi.org/10.31450/ukrjnd.4(76).2022.10
Номер
№ 4(76) (2022): Ukrainian Journal of Nephrology and Dialysis
Розділ
Школа нефролога
Creative Commons License

Ця робота ліцензується відповідно до Creative Commons Attribution 4.0 International License.